1. Home
  2. INBS vs CANF Comparison

INBS vs CANF Comparison

Compare INBS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INBS
  • CANF
  • Stock Information
  • Founded
  • INBS 2016
  • CANF 1994
  • Country
  • INBS United States
  • CANF Israel
  • Employees
  • INBS N/A
  • CANF N/A
  • Industry
  • INBS Medical Specialities
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • INBS Health Care
  • CANF Health Care
  • Exchange
  • INBS Nasdaq
  • CANF Nasdaq
  • Market Cap
  • INBS 11.7M
  • CANF 9.6M
  • IPO Year
  • INBS N/A
  • CANF N/A
  • Fundamental
  • Price
  • INBS $1.03
  • CANF $0.54
  • Analyst Decision
  • INBS
  • CANF Strong Buy
  • Analyst Count
  • INBS 0
  • CANF 2
  • Target Price
  • INBS N/A
  • CANF $14.50
  • AVG Volume (30 Days)
  • INBS 199.0K
  • CANF 278.2K
  • Earning Date
  • INBS 11-06-2025
  • CANF 11-27-2025
  • Dividend Yield
  • INBS N/A
  • CANF N/A
  • EPS Growth
  • INBS N/A
  • CANF N/A
  • EPS
  • INBS N/A
  • CANF N/A
  • Revenue
  • INBS $3,052,532.00
  • CANF $560,000.00
  • Revenue This Year
  • INBS $778.48
  • CANF $461.72
  • Revenue Next Year
  • INBS N/A
  • CANF N/A
  • P/E Ratio
  • INBS N/A
  • CANF N/A
  • Revenue Growth
  • INBS N/A
  • CANF N/A
  • 52 Week Low
  • INBS $1.01
  • CANF $0.47
  • 52 Week High
  • INBS $2.75
  • CANF $3.12
  • Technical
  • Relative Strength Index (RSI)
  • INBS 34.56
  • CANF 37.41
  • Support Level
  • INBS $1.02
  • CANF $0.47
  • Resistance Level
  • INBS $1.17
  • CANF $0.60
  • Average True Range (ATR)
  • INBS 0.07
  • CANF 0.03
  • MACD
  • INBS 0.00
  • CANF -0.00
  • Stochastic Oscillator
  • INBS 6.25
  • CANF 43.05

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: